{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:23:14Z","timestamp":1792650194519,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Neurotrophic keratopathy (NK) is a relatively uncommon, underdiagnosed degenerative corneal disease that is caused by damage to the ophthalmic branch of the trigeminal nerve by conditions such as herpes simplex or zoster keratitis, intracranial space-occupying lesions, diabetes, or neurosurgical procedures. Over time, epithelial breakdown, corneal ulceration, corneal melting (thinning), perforation, and loss of vision may occur. The best opportunity to reverse ocular surface damage is in the earliest stage of NK. However, patients typically experience few symptoms and diagnosis is often delayed. Increased awareness of the causes of NK, consensus on when and how to screen for NK, and recommendations for how to treat NK are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An 11-member expert panel used a validated methodology (a RAND\/UCLA modified Delphi panel) to develop consensus on when to screen for and how best to diagnose and treat NK. Clinicians reviewed literature on the diagnosis and management of NK then rated a detailed set of 735 scenarios. In 646 scenarios, panelists rated whether a test of corneal sensitivity was warranted; in 20 scenarios, they considered the adequacy of specific tests and examinations to diagnose and stage NK; and in 69 scenarios, they rated the appropriateness of treatments for NK. Panelist ratings were used to develop clinical recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>There was agreement on 94% of scenarios. Based on this consensus, we present distinct circumstances when we strongly recommend or may consider a test for corneal sensitivity. We also present recommendations on the diagnostic tests to be performed in patients in whom NK is suspected and treatment options for NK.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>These expert recommendations should be validated with clinical data. The recommendations represent the consensus of experts, are informed by published literature and experience, and may improve outcomes by helping improve diagnosis and treatment of patients with NK.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-021-02092-1","type":"journal-article","created":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T23:30:28Z","timestamp":1631057428000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Expert consensus on the identification, diagnosis, and treatment of neurotrophic keratopathy"],"prefix":"10.1186","volume":"21","author":[{"given":"Reza","family":"Dana","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjan","family":"Farid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Preeya K.","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedram","family":"Hamrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Karpecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathleen M.","family":"McCabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Nijm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay S.","family":"Pepose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Pflugfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Rapuano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arvind","family":"Saini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah N.","family":"Gibbs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Broder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"key":"2092_CR1","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.preteyeres.2018.04.003","volume":"66","author":"HS Dua","year":"2018","unstructured":"Dua HS, Said DG, Messmer EM, Rolando M, Benitez-del-Castillo JM, Hossain PN, et al. Neurotrophic keratopathy. Prog Retin Eye Res. 2018;66:107\u201331. https:\/\/doi.org\/10.1016\/j.preteyeres.2018.04.003.","journal-title":"Prog Retin Eye Res"},{"key":"2092_CR2","volume-title":"An evidence-based approach to the diagnosis and treatment of neurotrophic keratopathy","author":"N Afshari","year":"2020","unstructured":"Afshari N, Ahmad S, Hamrah P, Massaro-Giordano M, Shekhawat N, Starr CE. An evidence-based approach to the diagnosis and treatment of neurotrophic keratopathy; 2020."},{"issue":"2","key":"2092_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/aos.13844","volume":"97","author":"M Labetoulle","year":"2019","unstructured":"Labetoulle M, Baudouin C, Calonge M, Merayo-Lloves J, Boboridis KG, Akova YA, et al. Role of corneal nerves in ocular surface homeostasis and disease. Acta Ophthalmol. 2019;97(2):137\u201345. https:\/\/doi.org\/10.1111\/aos.13844.","journal-title":"Acta Ophthalmol"},{"key":"2092_CR4","first-page":"452","volume-title":"Current ocular therapy","author":"I Mackie","year":"1995","unstructured":"Mackie I. Neuroparalytic keratitis. In: Fraunfelder F, Roy F, Meyer S, editors. Current ocular therapy; 1995. p. 452\u20134."},{"issue":"5","key":"2092_CR5","doi-asserted-by":"publisher","first-page":"6108","DOI":"10.1002\/jcp.27345","volume":"234","author":"L Mastropasqua","year":"2019","unstructured":"Mastropasqua L, Nubile M, Lanzini M, Calienno R, Dua HS. In vivo microscopic and optical coherence tomography classification of neurotrophic keratopathy. J Cell Physiol. 2019;234(5):6108\u201315. https:\/\/doi.org\/10.1002\/jcp.27345.","journal-title":"J Cell Physiol"},{"key":"2092_CR6","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2147\/EB.S117261","volume":"10","author":"P Versura","year":"2018","unstructured":"Versura P, Giannaccare G, Pellegrini M, Sebastiani S, Campos EC. Neurotrophic keratitis: current challenges and future prospects. EB. 2018;10:37\u201345. https:\/\/doi.org\/10.2147\/EB.S117261.","journal-title":"EB"},{"key":"2092_CR7","doi-asserted-by":"publisher","first-page":"571","DOI":"10.2147\/OPTH.S45921","volume":"8","author":"M Sacchetti","year":"2014","unstructured":"Sacchetti M, Lambiase A. Diagnosis and management of neurotrophic keratitis. Clin Ophthalmol. 2014;8:571\u20139. https:\/\/doi.org\/10.2147\/OPTH.S45921.","journal-title":"Clin Ophthalmol"},{"issue":"6","key":"2092_CR8","doi-asserted-by":"publisher","first-page":"e20476","DOI":"10.1371\/journal.pone.0020476","volume":"6","author":"R Boulkedid","year":"2011","unstructured":"Boulkedid R, Abdoul H, Loustau M, Sibony O, Alberti C. Using and reporting the Delphi method for selecting healthcare quality indicators: a systematic review. Wright JM, ed. PLoS One. 2011;6(6):e20476. https:\/\/doi.org\/10.1371\/journal.pone.0020476.","journal-title":"PLoS One"},{"issue":"8","key":"2092_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1001\/jama.1995.03530080048040","volume":"274","author":"RL Kravitz","year":"1995","unstructured":"Kravitz RL, Laouri M, Kahan JP, Sherman T, Hilborne L, Brook RH. Validity of criteria used for detecting underuse of coronary revascularization. JAMA. 1995;274(8):632\u20138. https:\/\/doi.org\/10.1001\/jama.1995.03530080048040.","journal-title":"JAMA"},{"issue":"9","key":"2092_CR10","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1056\/NEJM200103013440906","volume":"344","author":"H Hemingway","year":"2001","unstructured":"Hemingway H, Crook AM, Feder G, Banerjee S, Dawson JR, Magee P, et al. Underuse of coronary revascularization procedures in patients considered appropriate candidates for revascularization. N Engl J Med. 2001;344(9):645\u201354. https:\/\/doi.org\/10.1056\/NEJM200103013440906.","journal-title":"N Engl J Med"},{"issue":"9","key":"2092_CR11","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1016\/j.jacc.2011.12.001","volume":"59","author":"MR Patel","year":"2012","unstructured":"Patel MR, Dehmer GJ, Hirshfeld JW, Smith PK, Spertus JA. ACCF\/SCAI\/STS\/AATS\/AHA\/ASNC\/HFSA\/SCCT 2012 Appropriate use criteria for coronary revascularization focused update: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, American Society of Nuclear Cardiology, and the Society of Cardiovascular Computed Tomography. J Am Coll Cardiol. 2012;59(9):857\u201381. https:\/\/doi.org\/10.1016\/j.jacc.2011.12.001.","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"2092_CR12","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.amjcard.2015.03.057","volume":"116","author":"SM Bradley","year":"2015","unstructured":"Bradley SM, Chan PS, Hartigan PM, Nallamothu BK, Weintraub WS, Sedlis SP, et al. Validation of the appropriate use criteria for percutaneous coronary intervention in patients with stable coronary artery disease (from the COURAGE trial). Am J Cardiol. 2015;116(2):167\u201373. https:\/\/doi.org\/10.1016\/j.amjcard.2015.03.057.","journal-title":"Am J Cardiol"},{"issue":"1","key":"2092_CR13","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1472-6963-6-24","volume":"6","author":"J Ma Quintana","year":"2006","unstructured":"Ma Quintana J, Escobar A, Bilbao A. Explicit criteria for prioritization of cataract surgery. BMC Health Serv Res. 2006;6(1):24. https:\/\/doi.org\/10.1186\/1472-6963-6-24.","journal-title":"BMC Health Serv Res"},{"issue":"9","key":"2092_CR14","doi-asserted-by":"publisher","first-page":"979","DOI":"10.2105\/AJPH.74.9.979","volume":"74","author":"A Fink","year":"1984","unstructured":"Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health. 1984;74(9):979\u201383. https:\/\/doi.org\/10.2105\/AJPH.74.9.979.","journal-title":"Am J Public Health"},{"issue":"4","key":"2092_CR15","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1136\/qhc.11.4.358","volume":"11","author":"SM Campbell","year":"2002","unstructured":"Campbell SM. Research methods used in developing and applying quality indicators in primary care. Qual Saf Health Care. 2002;11(4):358\u201364. https:\/\/doi.org\/10.1136\/qhc.11.4.358.","journal-title":"Qual Saf Health Care"},{"key":"2092_CR16","unstructured":"Fitch K, ed. The Rand\/UCLA appropriateness method user\u2019s manual. Santa Monica: Rand Corporation; 2001."},{"issue":"4","key":"2092_CR17","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.jtos.2019.09.002","volume":"17","author":"A Di Zazzo","year":"2019","unstructured":"Di Zazzo A, Coassin M, Varacalli G, Galvagno E, De Vincentis A, Bonini S. Neurotrophic keratopathy: pros and cons of current treatments. Ocul Surf. 2019;17(4):619\u201323. https:\/\/doi.org\/10.1016\/j.jtos.2019.09.002.","journal-title":"Ocul Surf"},{"issue":"9","key":"2092_CR18","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1016\/j.ophtha.2018.03.004","volume":"125","author":"S Bonini","year":"2018","unstructured":"Bonini S, Lambiase A, Rama P, Filatori I, Allegretti M, Chao W, et al. Phase I trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018;125(9):1468\u201371. https:\/\/doi.org\/10.1016\/j.ophtha.2018.03.004.","journal-title":"Ophthalmology"},{"issue":"9","key":"2092_CR19","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1016\/j.ophtha.2018.02.022","volume":"125","author":"S Bonini","year":"2018","unstructured":"Bonini S, Lambiase A, Rama P, Sinigaglia F, Allegretti M, Chao W, et al. Phase II randomized, double-masked, vehicle-controlled trial of recombinant human nerve growth factor for neurotrophic keratitis. Ophthalmology. 2018;125(9):1332\u201343. https:\/\/doi.org\/10.1016\/j.ophtha.2018.02.022.","journal-title":"Ophthalmology"},{"issue":"1","key":"2092_CR20","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.ophtha.2019.08.020","volume":"127","author":"SC Pflugfelder","year":"2020","unstructured":"Pflugfelder SC, Massaro-Giordano M, Perez VL, Hamrah P, Deng SX, Espandar L, et al. Topical recombinant human nerve growth factor (Cenegermin) for neurotrophic keratopathy. Ophthalmology. 2020;127(1):14\u201326. https:\/\/doi.org\/10.1016\/j.ophtha.2019.08.020.","journal-title":"Ophthalmology"},{"issue":"6","key":"2092_CR21","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1097\/01.ico.0000153102.19776.80","volume":"24","author":"S Khokhar","year":"2005","unstructured":"Khokhar S, Natung T, Sony P, Sharma N, Agarwal N, Vajpayee RB. Amniotic membrane transplantation in refractory neurotrophic corneal ulcers: a randomized, controlled clinical trial. Cornea. 2005;24(6):654\u201360. https:\/\/doi.org\/10.1097\/01.ico.0000153102.19776.80.","journal-title":"Cornea"},{"issue":"3","key":"2092_CR22","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3109\/08820538.2013.768678","volume":"29","author":"E Turkoglu","year":"2014","unstructured":"Turkoglu E, Celik E, Alagoz G. A comparison of the efficacy of autologous serum eye drops with amniotic membrane transplantation in neurotrophic keratitis. Semin Opthalmol. 2014;29(3):119\u201326. https:\/\/doi.org\/10.3109\/08820538.2013.768678.","journal-title":"Semin Opthalmol"},{"key":"2092_CR23","unstructured":"Dekaris I, Gabri N, Mravii I, Katu J. Multilayer vs. Monolayer Amniotic Membrane Transplantation for Deep Corneal Ulcer Treatment. Coll Antropol. 2001;25(Suppl:23-28):7."},{"key":"2092_CR24","first-page":"14","volume":"8","author":"U Vaidyanathan","year":"2019","unstructured":"Vaidyanathan U, Hopping GC, Liu HY, et al. Persistent corneal epithelial defects: a review article. Med Hypothesis Discov Innov Ophthalmol. 2019;8:14.","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"issue":"8","key":"2092_CR25","doi-asserted-by":"publisher","first-page":"989","DOI":"10.1038\/sj.eye.6700616","volume":"17","author":"S Bonini","year":"2003","unstructured":"Bonini S, Rama P, Olzi D, Lambiase A. Neurotrophic keratitis. Eye (Lond). 2003;17(8):989\u201395. https:\/\/doi.org\/10.1038\/sj.eye.6700616.","journal-title":"Eye (Lond)"},{"issue":"5","key":"2092_CR26","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1097\/ICL.0000000000000133","volume":"41","author":"HY Hsu","year":"2015","unstructured":"Hsu HY, Modi D. Etiologies, quantitative hypoesthesia, and clinical outcomes of neurotrophic keratopathy. Eye Contact Lens. 2015;41(5):314\u20137. https:\/\/doi.org\/10.1097\/ICL.0000000000000133.","journal-title":"Eye Contact Lens"},{"issue":"12","key":"2092_CR27","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/j.jocn.2015.04.030","volume":"22","author":"AY Nemet","year":"2015","unstructured":"Nemet AY, Vinker S. Considerations and complications after Bells\u2019 palsy. J Clin Neurosci. 2015;22(12):1949\u201353. https:\/\/doi.org\/10.1016\/j.jocn.2015.04.030.","journal-title":"J Clin Neurosci"},{"key":"2092_CR28","doi-asserted-by":"publisher","unstructured":"Dehghani C, Pritchard N, Edwards K, Russell AW, Malik RA, Efron N. Risk factors associated with corneal nerve alteration in type 1 diabetes in the absence of neuropathy: a longitudinal in vivo corneal confocal microscopy study. Cornea. 2016;35(6). https:\/\/doi.org\/10.1097\/ICO.0000000000000760.","DOI":"10.1097\/ICO.0000000000000760"},{"key":"2092_CR29","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.ajo.2019.09.010","volume":"209","author":"J Hafner","year":"2020","unstructured":"Hafner J, Zadrazil M, Grisold A, Ricken G, Krenn M, Kitzmantl D, et al. Retinal and corneal neurodegeneration and their association with systemic signs of peripheral neuropathy in type 2 diabetes. Am J Opthalmol. 2020;209:197\u2013205. https:\/\/doi.org\/10.1016\/j.ajo.2019.09.010.","journal-title":"Am J Opthalmol"},{"issue":"4","key":"2092_CR30","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1111\/jdi.12335","volume":"6","author":"N Papanas","year":"2015","unstructured":"Papanas N, Ziegler D. Corneal confocal microscopy: recent progress in the evaluation of diabetic neuropathy. J Diabetes Invest. 2015;6(4):381\u20139. https:\/\/doi.org\/10.1111\/jdi.12335.","journal-title":"J Diabetes Invest"},{"issue":"7","key":"2092_CR31","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1097\/01.ico.0000224640.58848.54","volume":"25","author":"MC Mocan","year":"2006","unstructured":"Mocan MC, Durukan I, Irkec M, Orhan M. Morphologic alterations of both the stromal and subbasal nerves in the corneas of patients with diabetes. Cornea. 2006;25(7):769\u201373. https:\/\/doi.org\/10.1097\/01.ico.0000224640.58848.54.","journal-title":"Cornea"},{"issue":"3","key":"2092_CR32","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1167\/iovs.61.3.48","volume":"61","author":"M Ferdousi","year":"2020","unstructured":"Ferdousi M, Kalteniece A, Petropoulos I, Azmi S, Dhage S, Marshall A, et al. Diabetic neuropathy is characterized by progressive corneal nerve fiber loss in the central and inferior whorl regions. Invest Ophthalmol Vis Sci. 2020;61(3):48. https:\/\/doi.org\/10.1167\/iovs.61.3.48.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"2092_CR33","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/00003226-200301000-00004","volume":"22","author":"J Saito","year":"2003","unstructured":"Saito J, Enoki M, Hara M, Morishige N, Chikama T, Nishida T. Correlation of corneal sensation, but not of basal or reflex tear secretion, with the stage of diabetic retinopathy. Cornea. 2003;22(1):15\u20138. https:\/\/doi.org\/10.1097\/00003226-200301000-00004.","journal-title":"Cornea"},{"issue":"1","key":"2092_CR34","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1136\/bjophthalmol-2014-306038","volume":"100","author":"M-S Jiang","year":"2016","unstructured":"Jiang M-S, Yuan Y, Gu Z-X, Zhuang S-L. Corneal confocal microscopy for assessment of diabetic peripheral neuropathy: a meta-analysis. Br J Ophthalmol. 2016;100(1):9\u201314. https:\/\/doi.org\/10.1136\/bjophthalmol-2014-306038.","journal-title":"Br J Ophthalmol"},{"issue":"2","key":"2092_CR35","first-page":"166","volume":"49","author":"R Sitompul","year":"2017","unstructured":"Sitompul R. Corneal sensitivity as a potential marker of diabetic neuropathy. Acta Med Indones. 2017;49(2):166\u201372.","journal-title":"Acta Med Indones"},{"issue":"1","key":"2092_CR36","doi-asserted-by":"publisher","first-page":"7388","DOI":"10.1038\/s41598-020-64489-0","volume":"10","author":"Y-S Chang","year":"2020","unstructured":"Chang Y-S, Tai M-C, Ho C-H, Chu CC, Wang JJ, Tseng SH, et al. Risk of corneal ulcer in patients with diabetes mellitus: a retrospective large-scale cohort study. Sci Rep. 2020;10(1):7388. https:\/\/doi.org\/10.1038\/s41598-020-64489-0.","journal-title":"Sci Rep"},{"issue":"10","key":"2092_CR37","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1097\/ICO.0b013e3181a2a7f6","volume":"28","author":"BH Jeng","year":"2009","unstructured":"Jeng BH, Dupps WJ. Autologous serum 50% eyedrops in the treatment of persistent corneal epithelial defects. Cornea. 2009;28(10):1104\u20138. https:\/\/doi.org\/10.1097\/ICO.0b013e3181a2a7f6.","journal-title":"Cornea"},{"key":"2092_CR38","doi-asserted-by":"publisher","unstructured":"Erdem E, Yagmur M, Harbiyeli I, Taylan-Sekeroglu H, Ersoz R. Umbilical cord blood serum therapy for the management of persistant corneal epithelial defects. Int J Opthalmol. 2014;7(5). https:\/\/doi.org\/10.3980\/j.issn.2222-3959.2014.05.12.","DOI":"10.3980\/j.issn.2222-3959.2014.05.12"},{"issue":"9","key":"2092_CR39","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1016\/j.ophtha.2006.12.014","volume":"114","author":"K-C Yoon","year":"2007","unstructured":"Yoon K-C, You I-C, Im S-K, Jeong T-S, Park Y-G, Choi J. Application of umbilical cord serum eyedrops for the treatment of neurotrophic keratitis. Ophthalmology. 2007;114(9):1637\u201342. https:\/\/doi.org\/10.1016\/j.ophtha.2006.12.014.","journal-title":"Ophthalmology"},{"key":"2092_CR40","doi-asserted-by":"publisher","unstructured":"Huang C-T, Chu H-S, Hung K-C, et al. The effect of human platelet lysate on corneal nerve regeneration. Br J Ophthalmol. 2019:bjophthalmol-2019-314408. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-314408.","DOI":"10.1136\/bjophthalmol-2019-314408"},{"key":"2092_CR41","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.ajo.2020.04.036","volume":"217","author":"L Mastropasqua","year":"2020","unstructured":"Mastropasqua L, Lanzini M, Dua HS, D\u2019Uffizi A, di Nicola M, Calienno R, et al. In vivo evaluation of corneal nerves and epithelial healing after treatment with recombinant nerve growth factor for neurotrophic keratopathy. Am J Ophthalmol. 2020;217:278\u201386. https:\/\/doi.org\/10.1016\/j.ajo.2020.04.036.","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"2092_CR42","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1089\/jop.2017.0010","volume":"33","author":"M Guerra","year":"2017","unstructured":"Guerra M, Marques S, Gil JQ, Campos J, Ramos P, Rosa AM, et al. Neurotrophic keratopathy: therapeutic approach using a novel matrix regenerating agent. J Ocul Pharmacol Ther. 2017;33(9):662\u20139. https:\/\/doi.org\/10.1089\/jop.2017.0010.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"5","key":"2092_CR43","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1097\/ICL.0b013e3182a2f8fa","volume":"39","author":"K Suri","year":"2013","unstructured":"Suri K, Kosker M, Raber IM, Hammersmith KM, Nagra PK, Ayres BD, et al. Sutureless amniotic membrane ProKera for ocular surface disorders: short-term results. Eye Contact Lens. 2013;39(5):341\u20137. https:\/\/doi.org\/10.1097\/ICL.0b013e3182a2f8fa.","journal-title":"Eye Contact Lens"},{"key":"2092_CR44","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.2147\/OPTH.S253750","volume":"14","author":"D Brocks","year":"2020","unstructured":"Brocks D, Mead OG, Tighe S, Scheffer TC. Self-retained cyropressed amniotic membrane for the management of corneal ulcers. Clin Opthalmol. 2020;14:1437\u201343. https:\/\/doi.org\/10.2147\/OPTH.S253750.","journal-title":"Clin Opthalmol"},{"issue":"5","key":"2092_CR45","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/IOP.0000000000001583","volume":"36","author":"JK Park","year":"2020","unstructured":"Park JK, Charlson ES, Leyngold I, Kossler AL. Corneal neurotization: a review of pathophysiology and outcomes. Ophthalmic Plast Reconstr Surg. 2020;36(5):431\u20137. https:\/\/doi.org\/10.1097\/IOP.0000000000001583.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"2092_CR46","doi-asserted-by":"publisher","unstructured":"Catapano J, Fung SSM, Halliday W, et al. Treatment of neurotrophic keratopathy with minimally invasive corneal neurotisation: long-term clinical outcomes and evidence of corneal reinnervation. Br J Ophthalmol. 2019:bjophthalmol-2018-313042. https:\/\/doi.org\/10.1136\/bjophthalmol-2018-313042.","DOI":"10.1136\/bjophthalmol-2018-313042"},{"key":"2092_CR47","unstructured":"U.S. National Library of Medicine. Clinical trials. Interventional studies. Neurotrophic keratitis search results. National Institute of Health. https:\/\/clinicaltrials.gov\/ct2\/results?cond=Neurotrophic+Keratitis&age_v=&gndr=&type=Intr&rslt=&Search=Apply. Accessed 4 Jan 2021."},{"issue":"2","key":"2092_CR48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.2105\/ajph.77.2.187","volume":"77","author":"NJ Merrick","year":"1987","unstructured":"Merrick NJ, Fink A, Park RE, Brook RH, Kosecoff J, Chassin MR, et al. Derivation of clinical indications for carotid endarterectomy by an expert panel. Am J Public Health. 1987;77(2):187\u201390. https:\/\/doi.org\/10.2105\/ajph.77.2.187.","journal-title":"Am J Public Health"},{"issue":"26","key":"2092_CR49","doi-asserted-by":"publisher","first-page":"1888","DOI":"10.1056\/NEJM199806253382607","volume":"338","author":"PG Shekelle","year":"1998","unstructured":"Shekelle PG, Kahan JP, Bernstein SJ, Leape LL, Kamberg CJ, Park RE. The reproducibility of a method to identify the overuse and underuse of medical procedures. N Engl J Med. 1998;338(26):1888\u201395. https:\/\/doi.org\/10.1056\/NEJM199806253382607.","journal-title":"N Engl J Med"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-02092-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-021-02092-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-021-02092-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T23:30:37Z","timestamp":1631057437000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-021-02092-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":49,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2092"],"URL":"https:\/\/doi.org\/10.1186\/s12886-021-02092-1","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]},"assertion":[{"value":"17 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. Our study did not involve human subjects as defined in 45 CFR part 46, thus institutional review board approval was not required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Authors report the following competing interests, as noted in the ICMJE forms submitted with the manuscript.RD: Reports personal fees from Domp\u00e9 during the conduct of the study; personal fees from Kala Pharmaceuticals, Novartis, GSK, and Claris Biotherapeutics; grants from Allergan and the NIH; other from Kera Therapeutics; and personal fees and other from Aramis Biosciences, GelMEDIX, and Claris Biotherapeutics outside the submitted work.MF: Reports personal fees from Domp\u00e9 during the conduct of the study; personal fees from Allergan, Bio-Tissue, CorneaGen, Domp\u00e9, EyePoint Pharmaceuticals, Eyevance, Johnson & Johnson Vision, Kala Pharmaceuticals, Novartis, and ZEISS outside the submitted work.PKG: Reports personal fees from Domp\u00e9 during the conduct of the study.PH: Reports personal fees from Domp\u00e9 during the conduct of the study; grants and personal fees from Domp\u00e9 and personal fees from Neuroptika outside the submitted work.PK: Reports personal fees from Domp\u00e9 during the conduct of the study; personal fees from Allergan\/AbbVie, Bausch + Lomb, Bio-Tissue, Cambium, Domp\u00e9, EyeGate Pharma, OASIS Medical, Regener-Eyes, Sun Pharma, Novartis, Surface Pharmaceuticals, and Vital Tears outside the submitted work.CMC: Reports personal fees from Domp\u00e9 during the conduct of the study; personal fees from Alcon, Aerie Pharmaceuticals, Bausch + Lomb, Johnson & Johnson Vision, Allergan, Novartis, Sun Pharma, Ivantis, Glaukos, ZEISS, Omeros, Ocular Therapeutix, EyePoint Pharmaceuticals, Sight Sciences, Engage Technologies Group, Science Based Health, MST, Ora, Domp\u00e9, and Tarsus outside the submitted work.LN: Reports personal fees from Domp\u00e9 during the conduct of the study; personal fees from Akorn, Allergan, Bruder Healthcare Company, EyePoint, Johnson & Johnson Vision, Kala Pharmaceuticals, LarciScience, Novartis, Alcon Pharmaceuticals, Omeros Corporation, Sun Pharma, and ZEISS; other from MDNegotiation.com; and grants and personal fees from Ocular Therapeutix outside the submitted work.JSP: Reports personal fees from Domp\u00e9 during the conduct of the study; personal fees from Allergan, Bausch + Lomb, BRIM Biotechnology, Johnson & Johnson Vision, Keeler, Mimetogen, Novartis, OcuNexus, Ocuphire Pharma, Okogen, Stuart Pharmaceuticals, Sun Pharma, Th\u00e9a, TearLab, and Domp\u00e9; and grants and personal fees from AcuFocus and Kala Pharmaceuticals outside the submitted work.SP: Reports personal fees from Domp\u00e9 during the conduct of the study; personal fees from Kala Pharmaceuticals and Novartis, and grants and personal fees from Domp\u00e9 outside the submitted work.CJR: Reports personal fees from Domp\u00e9 during the conduct of the study; personal fees from Glaukos, Kala Pharmaceuticals, Novartis, Oyster Point Pharma, Sun Ophthalmics, TearLab, and Bio-Tissue outside the submitted work.AS: Reports personal fees from Domp\u00e9 during the conduct of the study.MSB, SNG: Are employees of the Partnership for Health Analytic Research (PHAR), LLC, which received an Independent Medical Education Grant from Domp\u00e9 US, Inc. (Grant ID: 87) to conduct the research described in this manuscript.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"327"}}